HBB-SABR (version 1.0)
Research type
Research Study
Full title
HBB-SABR: A feasibility study investigating the effect of hyoscine butylbromide injections on cone beam CT quality when delivering abdomino-pelvic stereotactic ablative radiotherapy (SABR)
IRAS ID
252816
Contact name
Finbar Slevin
Contact email
Sponsor organisation
University of Leeds
ISRCTN Number
ISRCTN24362767
Duration of Study in the UK
2 years, months, days
Research summary
Title: HBB-SABR: A feasibility study investigating the effect of hyoscine butylbromide injections on cone beam CT quality when delivering abdomino-pelvic stereotactic ablative radiotherapy (SABR).\n\nBackground: Stereotactic ablative radiotherapy (SABR) is a type of radiotherapy where a high dose of radiation is given very accurately in a small number of treatments to an area of cancer and a limited region of normal tissue around it. It can be used to treat cancer in the lower abdomen and pelvis. Cone beam computed tomography (CBCT) scans are performed before each SABR treatment to check the treatment will be given to the right place. These scans are negatively affected by bowel movement. Hyoscine butylbromide (HBB) is routinely used in x-ray departments to reduce bowel movement and improve image quality but it is not used in radiotherapy. Improving image quality would potentially improve the ability to accurately give SABR to patients. HBB is well tolerated by most patients.\n\nStudy population: 20 participants with limited areas of cancer in the lower abdomen and pelvis being treated with SABR in Leeds and other UK radiotherapy centres. \n\nIntervention: Participants will be given HBB as an injection into the muscle of the buttocks before alternate SABR treatments. Giving HBB on alternate SABR treatments would help show whether any improvement in CBCT image quality was due to HBB or due to variation in that participant’s bowel motion. A questionnaire will be used to ask participants about any side effects from HBB, and if radiotherapy staff feel HBB could be used as a routine part of giving SABR. No further requirements of participants in the study are needed once their SABR treatment has finished.\n
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
19/YH/0074
Date of REC Opinion
28 May 2019
REC opinion
Further Information Favourable Opinion